FASN and Burkitt lymphoma: From this, we can conclude that USP2a inhibition selectively inhibits the proliferation of LMP1-positive BL cell lines, providing a rationale for a future investigation of ML364 treatment of LMP1-positive malignancies and solidifying another example of USP2a-induced stabilization of FASN in a third, separate human cancer.